Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Pantoprazole sodium sesquihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for 2. What you need to know before you take Pantoprazole 3. How to take Pantoprazole 4. Possible side effects 5. How to store Pantoprazole 6. Contents of the pack and other information
Adults and adolescents 12 years of age and above:
e Pantoprazole Do not take Pantoprazole
smer vlaken/direction on fibre
70 mm ± 0,5 mm
111
520 mm ± 0,8 mm
magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.
If you take Pantoprazole on a long-term basis (longer than 1 year) your doctor will probably keep you under regular surveillance. You should report any new and exceptional symptoms and circumstances whenever you see your doctor. This medicine may affect the way that your body absorbs vitamin B12, particularly if you need to take it for a long time. Please contact your doctor if you notice any of the following symptoms, which could indicate low levels of Vitamin B12:
70 mm ± 0,5 mm
Pantoprazole Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
:ffl
smer branja kode/direction of reading PhC
When and how should you take Pantoprazole? Take the tablets 1 hour before a meal without chewing or breaking them and swallow them whole with some water. Unless told otherwise by your doctor, the recommended dose is: Adults and adolescents 12 years of age and above: To treat symptoms (e.g. heartburn, acid regurgitation, pain on swallowing) associated to gastro-oesophageal reflux disease The recommended dose is one tablet a day. This dose usually brings relief within 2 – 4 weeks – at most after another 4 weeks. Your doctor will tell you how long to continue taking the medicine. After this any recurring symptoms can be controlled by taking one tablet daily, when required. For long-term management and for preventing the return of reflux oesophagitis The recommended dose is one tablet a day. If the illness returns, your doctor can double the dose, in which case you can use Pantoprazole 40 mg tablets instead, one a day. After healing, you can reduce the dose back again to one tablet 20 mg a day. Adults: To prevent duodenal and stomach ulcers in patients who need to take NSAIDs continuously The recommended dose is one tablet a day. Special patient groups:
Leaflet folded on middle with visibly first side (title); PhC that comes out of the middle of leaflet must be visible!/ Navodila prepognjena na sredini z vidno prvo stranjo (naslovom); pharma kodi, ki izhajata iz sredine navodila, morata biti vidni!
Oddelek za oblikovanje/Packaging Design MockUp014398_1
If you take more Pantoprazole than you should Tell your doctor or pharmacist. There are no known symptoms of overdose. If you forget to take Pantoprazole Do not take a double dose to make up for a forgotten dose. Take your next normal dose at the usual time. If you stop taking Pantoprazole Do not stop taking these tablets without first talking to your doctor or pharmacist. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
148 mm ± 0,5 mm
4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. If you get any of the following side effects, stop taking these tablets and tell your doctor immediately, or contact the casualty department at your nearest hospital: Serious allergic reactions (frequency rare (may affect up to 1 in 1,000 people)):
smer branja kode/direction of reading PhC
130 mm ± 0,5 mm
identified through blood tests: Uncommon (may affect up to 1 in 100 people)
Blister pack: Store in the original package in order to protect from moisture.
A plastic container of 100 and 250 gastro-resistant tablets.
Very rare (may affect up to 1 in 10,000 people)
Container: Keep the container tightly closed in order to protect from moisture. After first opening of the container, the product should be used within 3 months.
Marketing Authorisation Holder KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Not known (frequency cannot be estimated from the available data)
Pantoprazole Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date refers to the last day of that month. This medicine does not require any special temperature storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Not all pack sizes may be marketed.
Manufacturer KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, D-27472 Cuxhaven, Germany This leaflet was last revised in 06/2023.
What Pantoprazole contains
XXXXXX
NA./PL. Pantoprazole 20 mg gastro-resistant tablets GB druga stran/second page
III smer vlaken/direction on fibre
520 mm ± 0,8 mm
130 mm ± 0,5 mm
smer branja kode/direction of reading PhC
Pantoprazole 20 mg gastro-resistant tablet comes as tablet containing 20mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Pantoprazole 20 mg gastro-resistant tablet is pantoprazole sodium sesquihydrate.
Medicines with the same active substance, strength and form include: Pantoprazole 20 mg gastro-resistant tablets, Pantoprazole 20 mg gastro-resistant tablets, Pantoprazole 20mg Gastro-resistant Tablets. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Pantoprazole 20 mg gastro-resistant tablet, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.
Posology
The recommended dose is 20 mg pantoprazole (one tablet) per day.
It might be necessary to take the tablets for 2-3 consecutive days to achieve improvement of symptoms. Once complete relief of symptoms has occurred, treatment should be discontinued. The treatment should not exceed 4 weeks without consulting a doctor.
If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor.
Special populations
No dose adjustment is necessary in elderly patients or in those with impaired renal or liver function.
Paediatric population
Pantoprazole Krka is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy.
Method of administration
Pantoprazole Krka 20 mg gastro-resistant tablets should not be chewed or crushed, and should be swallowed whole with liquid before a meal.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, nelfinavir; due to significant reduction in their bioavailability(see section 4.5).
Patients should be instructed to consult a doctor if:
- They have unintentional weight loss, anaemia, gastrointestinal bleeding, dysphagia, persistent vomiting or vomiting with blood, since pantoprazole may alleviate symptoms and delay diagnosis of a severe condition. In these cases, malignancy should be excluded.
- They have had previous gastric ulcer or gastrointestinal surgery.
- They are on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks.
- They have jaundice, hepatic impairment, or liver disease.
- They have any other serious disease affecting general well-being.
- They are aged over 55 years with new or recently changed symptoms.
Patients with long-term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals. Especially, patients over 55 years taking any non-prescription indigestion or heartburn remedy on a daily basis should inform their pharmacist or doctor.
Patients should not take another proton pump inhibitor or H2 antagonist concomitantly.
Patients should consult their doctor before taking this medicinal product if they are due to have an endoscopy or urea breath test.
Patients should be advised that the tablets are not intended to provide immediate relief.
Patients may start to experience symptomatic relief after approximately one day of treatment with pantoprazole, but it might be necessary to take it for 7 days to achieve complete heartburn control. Patients should not take pantoprazole as a preventive medicinal product.
Gastrointestinal infections caused by bacteria
Decreased gastric acidity, due to any means - including proton pump inhibitors - increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with acidreducing medicinal products leads to a slightly increased risk of gastrointestinal infections such as Salmonella, Campylobacter, or C. difficile.
Subacute cutaneous lupus erythematosus (SCLE)
Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Pantoprazole Krka. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.
Interference with laboratory tests
Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Pantoprazole Krka treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.
This medicinal product is intended for short-term use (up to 4 weeks) only (Refer to section 4.2). Patients should be warned about additional risks with long-term use of the medicinal products and the need for prescription and regular surveillance should be emphasized.
The following additional risks are considered relevant for long-term use:
Influence on vitamin B12 absorption:
Pantoprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed.
Bone Fracture:
Proton pump inhibitors, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in older people or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10–40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.
Hypomagnesemia:
Severe hypomagnesaemia has been rarely reported in patients treated with proton pump inhibitors (PPIs) like pantoprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness, and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. Hypomagnesaemia may lead to hypocalcaemia and/or hypokalaemia (see section 4.8). In most affected patients, hypomagnesaemia (and hypomagnesaemia associated hypocalcaemia and/or hypokalaemia) improved after magnesium replacement and discontinuation of the PPI.
For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products that may cause hypomagnesaemia (e.g. diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.
Pantoprazole Krka contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
Medical products with pH dependent absorption pharmacokinetics
Pantoprazole Krka may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH (e.g. ketoconazole).
HIV protease inhibitors:
Co-administration of pantoprazole is contraindicated with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, nelfinavir; due to significant reduction in their bioavailability(see section 4.3).
Coumarin anticoagulants (phenoprocoumon or warfarin)
Although no interaction during concomitant administration of phenprocoumon or warfarin has been observed in clinical pharmacokinetic studies, a few isolated cases of changes in International Normalised Ratio (INR) have been reported during concomitant treatment in the post-marketing period. Therefore, in patients treated with coumarin anticoagulants (e.g. phenprocoumon or warfarin), monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular use of pantoprazole.
Methotrexate
Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients. Therefore in settings where high-dose methotrexate is used, for example caner and psoriasis, a temporary withdrawal of pantoprazole may need to be considered
Other interactions studies
Pantoprazole is metabolized in the liver via the cytochrome P450 enzyme system. Interaction studies with carbamazepine, caffeine, diazepam, diclofenac, digoxin, ethanol, glibenclamide, metoprolol, naproxen, nifedipine, phenytoin, piroxicam, theophylline and an oral contraceptive containing levonorgestrel and ethinyl oestradiol did not reveal clinically significant interactions. However, an interaction of pantoprazole with other substances which are metabolised by the same enzyme system cannot be excluded.
There were no interactions with concomitantly administered antacids.
Pregnancy
There are no adequate data from the use of pantoprazole in pregnant women. Studies in animals have shown reproductive toxicity. Preclinical studies revealed no evidence of impaired fertility or teratogenic effects (see section 5.3). The potential risk for humans is unknown. Pantoprazole should not be used during pregnancy.
Breast-feeding
Pantoprazole/metabolites have been identified in human milk. The effect of pantoprazole on newborns/infants is unknown. Pantoprazole Krka should not be used during breast-feeding.
Fertility
There was no evidence of impaired fertility following the administration of pantoprazole in animal studies (see section 5.3).
Pantoprazole Krka has no or negligible influence on the ability to drive and use machines. However adverse reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or use machines.
Summary of the safety profile
Approximately 5% of patients can be expected to experience adverse reactions.
Tabulated list of adverse reactions
The following adverse reactions have been reported with pantoprazole.
Within the following table, adverse reactionsare ranked under the MedDRA frequency classification: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data)
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Table 1. Undesirable effects with pantoprazole in clinical trials and post-marketing experience
Frequency System Organ Class
Common
Uncommon
Rare
Very rare
Not known
Blood and lymphatic system disorders
Agranulocytosis
Thrombocytopenia;
Leucopenia;
Pancytopenia
Hallucination;
Immune system disorders
Hypersensitivity (including anaphylactic reactions and anaphylactic shock)
Metabolism and nutrition disorders
Hyperlipidaemias and lipid increases (triglycerides, cholesterol);
Weight changes
Hyponatraemia;
Hypomagnesaemia
Hypocalcaemia(1)
Hypokalaemia(1)
Psychiatric disorders
Sleep disorders
Depression (and all aggravations)
Disorientation (and all aggravations)
Hallucination;
Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in case of pre-existence)
Nervous system disorders
Headache;
Dizziness
Taste disorders
Eye disorders
Disturbances in vision / blurred vision
Gastrointestinal disorders
Fundic gland polyps (benign)
Diarrhoea;
Nausea / vomiting;
Abdominal distension and bloating;
Constipation;
Dry mouth;
Abdominal pain and discomfort
Microscopic colitis
Hepatobiliary disorders
Liver enzymes increased (transaminases, γ-GT)
Bilirubin increased
Hepatocellular injury;
Jaundice;
Hepatocellular failure
Skin and subcutaneous tissue disorders
Rash / exanthema / eruption;
Pruritus
Urticaria;
Angioedema
Stevens-Johnson syndrome;
Lyell syndrome;
Erythema multiforme;
Drug reaction with eosinophilia and systemic symptoms (DRESS)
Photosensitivity;
Subacute cutaneous lupus erythematosus (see section 4.4)
Musculoskeletal, connective tissue disorders
Fracture of wrist, hip and spine
Arthralgia;
Myalgia
Renal and urinary disorders
Interstitial nephritis
Reproductive system and breast disorders
Gynaecomastia
General disorders and administration site conditions
Asthenia, fatigue and malaise
Body temperature increased;
Oedema peripheral
(1) Hypocalcaemia and/or hypokalaemia may be related to the occurrence of hypomagnesaemia (see section 4.4)
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
There are no known symptoms of overdose in man.
Doses up to 240 mg administered intravenously over 2 minutes were well tolerated.
Management
As pantoprazole is extensively protein bound, it is not readily dialysable.
In the case of overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.
Ask anything about Pantoprazole 20 mg gastro-resistant tablet. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.